FDA approves new drug to protect babies from RSV
CBSN
The Food and Drug Administration announced Monday it had approved a new kind of immunization to protect babies from RSV, or respiratory syncytial virus. The drug, nirsevimab, is one of two new options doctors hope could soon prevent the leading cause of hospitalization facing American infants.
Outside advisers to the federal government have previously hailed nirsevimab's showing in clinical trials as potentially "groundbreaking" for protecting babies. A panel of the FDA's outside experts voted in June to back the drug's safety and efficacy.
"Today's approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system," the FDA's Dr. John Farley, director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research, said in a statement.

As the Trump administration continues to prepare military options for strikes in Iran, U.S. allies in the Mideast, including Turkey, Oman and Qatar, are attempting to head off that possibility by brokering diplomatic talks, multiple regional officials told CBS News. Camilla Schick and Eleanor Watson contributed to this report.

Another winter storm may be headed toward the East Coast of the United States this weekend, on the heels of a powerful and deadly system that blanketed huge swaths of the country in snow and ice. The effects of that original storm have lingered for many areas in its path, and will likely remain as repeated bouts of Arctic air plunge downward from Canada and drive temperatures below freezing. Nikki Nolan contributed to this report. In:











